English
Email Chinese

Facts

I-Mab Biopharma was established through a merger of Third Venture Biopharma and Tasgen in 2017, aiming to develop innovative biologics in the areas of immuno-oncology and autoimmune disease for the global markets, including China;
Management team has combined and extensive global and domestic pharma leadership experiences in innovative drug development, covering discovery, CMC, pre-clinical development, regulatory and clinical development expertise;
Current pipeline is composed of 12 projects in two portfolios, i.e. “In China for Global” and “In China for China”. It includes 3 clinical assets (1 Ph 1 and 2 Ph 2 ready assets) and 6-7 innovative assets at CMC or pre-clinical development stage with China and US clinical development plans;
R&D model combines effectively in-house R&D core capabilities in discovery, CMC, pre-clinical and clinical development with preferred CROs of global standards, e.g. Wuxi Biologics, Covance, Mabplex, Tigermed through strategic partnerships;
Current shareholders include C-Bridge/I-Bridge Capital, Management team, Genexine, Tasly Pharmaceuticals, Simcere Pharmaceuticals, TigerMed, Partners Investment, Qianhai Capital, Anlong Capital etc. Series B financing of $150 million was completed in May 2017.

News

  • 2018 / 11 /3

    I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy A Potential Global First-in-Class Long-Acting IL-7

    SHANGHAI, Nov. 02, 2018 – I-MAB Biopharma Co., Ltd. ("I-Mab"), a Shanghai-based biotech company exclusively focused on innovative biologics in immuno-oncology and autoimmune diseases, and Genexine Inc. (KOSDAQ: 095700)... Read More >

  • I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy A Potential Global First-in-Class Long-Acting IL-7
    First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)
    I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs


    Address: Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China, 201210    Tel:86-21-6057 8000     Email:marcom@i-mabbiopharma.com